| Q2 2023 Results - 34 -
Cash Flow | H1 2023
Annex
1H 2022
Grifols incl. Biotest
In thousands of euros Reported Restructuring costs Transaction costs Diagnostic true-up
commercial Total one-offs Reported excl.
One-offs Reported Total one-offs Reported excl.
One-offs Reported Reported Reported excl.
One-offs
Reported Group Profit (11,498) 104,144 10,948 (9,432) 105,660 94,162 (44,723) (56,221) 105,660 49,439 143,649 -139% -66%
Depreciation and Amortization 189,568 - - - - 189,568 36,860 226,428 - 226,428 187,208 21% 21%
Net Provisions 75,073 (34,112) - - (34,112) 40,961 768 75,840 (34,112) 41,728 10,167 646% 310%
Other Adjustments and Other Changes in Working Capital (56,197) 35,450 3,649 (9,398) 29,701 (26,495) 5,300 (50,896) 29,701 (21,194) (67,958) -25% -69%
Change in Operating Working Capital (229,827) (21,963) - 18,830 (3,133) (232,959) (69,059) (298,886) (3,133) (302,019) (241,535) 24% 25%
Changes in Inventories (137,595) - - - - (137,595) (60,631) (198,226) - (198,226) (228,441) -13% -13%
Change in Trade Receivables (61,094) - - 18,830 18,830 (42,264) (24,552) (85,646) 18,830 (66,816) (44,810) 91% 49%
Change in Trade Payables (31,138) (21,963) - - (21,963) (53,101) 16,124 (15,014) (21,963) (36,977) 31,716 - -
Net Cash Flow From Operating Activities (32,880) 83,519 14,598 - 98,116 65,236 (70,854) (103,735) 98,116 (5,618) 31,531 - -
Business Combinations and Investments in Group Companies - - - - - - - - - - (1,545,046) - -
CAPEX (71,834) - - - - (71,834) (13,575) (85,408) - (85,408) (123,975) -31% -31%
R&D/Other Intangible Assets (32,559) - - - - (32,559) (8,112) (40,671) - (40,671) (19,066) 113% 113%
Other Cash Inflow / (Outflow) (53,448) - - - - (53,448) 46,657 (6,792) - (6,792) (108,965) -94% -94%
Net Cash Flow From Investing Activities (157,841) - - - - (157,841) 24,970 (132,871) - (132,871) (1,797,052) -93% -93%
Free Cash Flow (190,721) 83,519 14,598 - 98,116 (92,605) (45,884) (236,605) 98,116 (138,489) (1,765,521) -87% -92%
Issue / /Repayment) of Debt 217,978 - - - - 217,978 (2,504) 215,475 - 215,475 - - -
Capital Grants 1,367 - - - - 1,367 - 1,367 - 1,367 (447,431) - -
Dividends (Paid) / Received - - - - - - - - - - 3,927 - -
Other Cash Flows From / (Used in) Financing Activities 2,105 - - - - 2,105 - 2,105 - 2,105 10,816 -81% -81%
Net Cash Flow From Financing Activities 221,451 - - - - 221,451 (2,504) 218,947 - 218,947 (432,688) - -
Total Cash Flow 30,729 83,519 14,598 - 98,116 128,846 (48,388) (17,659) 98,116 80,458 (2,198,209) -99% -104%
Cash and Cash Equivalents at the Beginning of the Year 431,337 - - - - 431,337 116,642 547,979 - 547,979 2,675,611 -80% -80%
Effect of Exchange Rate Changes in Cash and Cash Equivalents (7,018) - - - - (7,018) 50 (6,968) - (6,968) 47,692 -115% -115%
Cash and Cash Equivalents at the End of the Period 455,048 83,519 14,598 - 98,116 553,164 68,304 523,352 98,116 621,469 525,094 0% 18%
H1 2023
Grifols excl. Biotest
Biotest
Grifols incl. Biotest
% vs PY
Grifols incl. Biotest |